Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. The company's products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease. In addition, it develops Aripiprazole TDS for the treatment for psychiatric disorders; Corplex Ropinirole, a transdermal patch for the treatment of Parkinson's disease; and Motion Sickness Patch, a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Agile Therapeutics, Inc.; and Aequus Pharmaceuticals, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-298-8255
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$31.86 million
Profitability
Miscellaneous
Employees213
OptionableOptionable
Corium International (NASDAQ:CORI) Frequently Asked Questions
What is Corium International's stock symbol?
Corium International trades on the NASDAQ under the ticker symbol "CORI."
How were Corium International's earnings last quarter?
Corium International Inc (NASDAQ:CORI) posted its quarterly earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. View Corium International's Earnings History.
What price target have analysts set for CORI?
3 analysts have issued 1-year target prices for Corium International's shares. Their predictions range from $13.00 to $14.00. On average, they expect Corium International's stock price to reach $13.50 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price. View Analyst Price Targets for Corium International.
What is the consensus analysts' recommendation for Corium International?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corium International in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Corium International.
What are Wall Street analysts saying about Corium International stock?
Here are some recent quotes from research analysts about Corium International stock:
- 1. According to Zacks Investment Research, "Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. " (8/14/2018)
- 2. HC Wainwright analysts commented, "Our $13 12-month target is based on a DCF reflecting an 11.5% WACC discount and 1.5% terminal growth beyond fiscal 2026. Our model only explicitly includes the base-business, and U.S. partner revenue for the donepezil patch (launch 1Q20) and Twirla (launch calendar 2H19, but not in the stock now after partner setbacks). The donepezil patch has IP to 2037 and Twirla has issued patents to 2028." (8/13/2018)
- 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $14 12-month PT for CORI stock. We maintain our belief that the donepezil Corplex patch will become an important new method for delivering a mainstay Alzheimer’s disease (AD) symptomatic treatment. We view successful development as a meaningful turning point in the company’s evolution and believe the investor base could broaden thereafter. Visibility as to other pipeline candidates could be an important driver of incremental share value too." (8/10/2018)
Has Corium International been receiving favorable news coverage?
News coverage about CORI stock has trended positive recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Corium International earned a media sentiment score of 2.6 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the stock's share price in the next few days.
Who are some of Corium International's key competitors?
Some companies that are related to Corium International include Allakos (ALLK), Zogenix (ZGNX), Corcept Therapeutics (CORT), Insmed (INSM), Madrigal Pharmaceuticals (MDGL), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Portola Pharmaceuticals (PTLA), Vanda Pharmaceuticals (VNDA), Pacira Pharmaceuticals (PCRX), Zai Lab (ZLAB), Theravance Biopharma (TBPH), Enanta Pharmaceuticals (ENTA), The Medicines (MDCO) and Prestige Consumer Healthcare (PBH).
Who are Corium International's key executives?
Corium International's management team includes the folowing people:
- Mr. Peter D. Staple, Pres, CEO & Director (Age 66)
- Mr. Robert S. Breuil, Chief Financial Officer (Age 56)
- Dr. Parminder Singh, CTO & VP of R&D (Age 54)
- Mr. Timothy D. Sweemer CPA, Chief Accounting Officer, VP of Admin. & Sec.
- Ms. Christina Dickerson, VP of Corp. Devel.
How do I buy shares of Corium International?
Shares of CORI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corium International's stock price today?
One share of CORI stock can currently be purchased for approximately $12.68.
How big of a company is Corium International?
Corium International has a market capitalization of $459.65 million and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Corium International employs 213 workers across the globe.
What is Corium International's official website?
How can I contact Corium International?
Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]
MarketBeat Community Rating for Corium International (NASDAQ CORI)
MarketBeat's community ratings are surveys of what our community members think about Corium International and other stocks. Vote "Outperform" if you believe CORI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CORI will underperform the S&P 500 over the long term. You may vote once every thirty days.
